Tomer M. Mark
About
Tomer M. Mark is a scholar working on Hematology, Molecular Biology and Oncology.
According to data from OpenAlex, Tomer M. Mark has authored 115 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Hematology, 63 papers in Molecular Biology and 57 papers in Oncology. Recurrent topics in Tomer M. Mark's work include Multiple Myeloma Research and Treatments (94 papers), Protein Degradation and Inhibitors (45 papers) and Peptidase Inhibition and Analysis (24 papers). Tomer M. Mark is often cited by papers focused on Multiple Myeloma Research and Treatments (94 papers), Protein Degradation and Inhibitors (45 papers) and Peptidase Inhibition and Analysis (24 papers). Tomer M. Mark collaborates with scholars based in United States, Germany and Spain. Tomer M. Mark's co-authors include Rubén Niesvizky, Ajay K. Nooka, Andrew Spencer, Ivan Špıčka, Vânia Hungria, Pieter Sonneveld, Tamás Masszi, Katja Weisel, María‐Victoria Mateos and Xiang Qin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Tomer M. Mark
108 papers receiving 2.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tomer M. Mark United States | 20 | 1.9k | 1.5k | 1.2k | 332 | 253 | 115 | 2.5k | ||
| Cristina Gasparetto United States | 30 | 2.0k 1.1× | 1.4k 1.0× | 1.2k 1.0× | 377 1.1× | 519 2.1× | 128 | 2.7k | ||
| Christoph Heuck United States | 23 | 1.3k 0.7× | 1.1k 0.7× | 851 0.7× | 267 0.8× | 413 1.6× | 101 | 2.1k | ||
| Nikoletta Lendvai United States | 26 | 1.2k 0.6× | 915 0.6× | 839 0.7× | 173 0.5× | 327 1.3× | 111 | 2.0k | ||
| P. Joy Ho Australia | 25 | 1.3k 0.7× | 937 0.6× | 891 0.7× | 450 1.4× | 786 3.1× | 113 | 2.2k | ||
| Yvonne A. Efebera United States | 27 | 1.4k 0.8× | 1.0k 0.7× | 1.6k 1.3× | 170 0.5× | 1.4k 5.5× | 150 | 3.0k | ||
| Douglas Joshua Australia | 25 | 1.0k 0.5× | 751 0.5× | 679 0.6× | 179 0.5× | 548 2.2× | 65 | 1.7k | ||
| Hugh D Carr-Smith United Kingdom | 10 | 912 0.5× | 1.1k 0.7× | 363 0.3× | 364 1.1× | 141 0.6× | 14 | 1.6k | ||
| Masao Mizuki Japan | 22 | 920 0.5× | 1.2k 0.8× | 518 0.4× | 478 1.4× | 669 2.6× | 47 | 2.3k | ||
| Steven Arkin United States | 24 | 1.7k 0.9× | 621 0.4× | 301 0.3× | 693 2.1× | 258 1.0× | 53 | 2.5k | ||
| Christopher S. Hourigan United States | 28 | 1.6k 0.8× | 814 0.5× | 444 0.4× | 376 1.1× | 590 2.3× | 106 | 2.5k |
Countries citing papers authored by Tomer M. Mark
Since
Specialization
Citations
This map shows the geographic impact of Tomer M. Mark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomer M. Mark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomer M. Mark more than expected).
Fields of papers citing papers by Tomer M. Mark
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Tomer M. Mark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomer M. Mark. The network helps show where Tomer M. Mark may publish in the future.
Co-authorship network of co-authors of Tomer M. Mark
This figure shows the co-authorship network connecting the top 25 collaborators of Tomer M. Mark. A scholar is included among the top collaborators of Tomer M. Mark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomer M. Mark. Tomer M. Mark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Thomas, Michael, Joachim G.J.V. Aerts, James D’Olimpio, et al.. (2025). 128TiP: ABBIL1TY NSCLC-06: A global, randomized, open-label, phase III trial of acasunlimab in combination with pembrolizumab (Pembro) vs docetaxel in checkpoint inhibitor (CPI)-experienced patients with PD-L1+ metastatic non-small cell lung cancer (mNSCLC). Journal of Thoracic Oncology. 20(3). S91–S92.
2.
Mark, Tomer M., et al.. (2025). Immature Platelets and Platelet Reactivity in Patients with COVID-19. Clinical and Applied Thrombosis/Hemostasis. 31. 3015499824–3015499824.
3.
Dima, Danai, Adriana Rossi, Tomer M. Mark, et al.. (2024). P-408 Survival Analysis of Selinexor-Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Real-World Exploratory Analysis. Clinical Lymphoma Myeloma & Leukemia. 24. S270–S270.
4.
Arinsburg, Suzanne, Tomer M. Mark, Christopher A. Fausel, et al.. (2024). Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma. Bone Marrow Transplantation. 59(10). 1440–1448.
5.
Walker, Zachary J., Krysta L. Engel, Zenggang Pan, et al.. (2024). Single-Cell RNA Sequencing before and after Light Chain Escape Reveals Intrapatient Multiple Myeloma Subpopulations with Divergent Osteolytic Gene Expression. Cancer Research Communications. 5(1). 106–118.
6.
Binder, Adam, Christopher J. Walker, Tomer M. Mark, & Muhamed Baljević. (2023). Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors. Frontiers in Immunology. 14. 1275329–1275329.
7.
Walker, Zachary J., Brett M. Stevens, Andrew Hammes, et al.. (2020). Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clinical Cancer Research. 27(3). 819–830.
8.
Mark, Tomer M., Paul J. Christos, Usama Gergis, et al.. (2019). High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation. 54(12). 2027–2038.
9.
Ely, Scott, Peter A. Forsberg, Adriana Rossi, et al.. (2017). Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clinical Lymphoma Myeloma & Leukemia. 17(12). 825–833.
10.
Forsberg, Peter A., Adriana Rossi, Roger Pearse, et al.. (2016). Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM). Blood. 128(22). 4518–4518.
11.
Runcie, Karie & Tomer M. Mark. (2015). Novel Induction Regimens in Multiple Myeloma. Current Hematologic Malignancy Reports. 10(4). 388–394.
12.
Krishnan, Udhay, Tomer M. Mark, Rubén Niesvizky, & Irina Sobol. (2015). Pulmonary Hypertension Complicating Multiple Myeloma. Pulmonary Circulation. 5(3). 590–597.
13.
Niesvizky, Rubén, Tomer M. Mark, Maureen Ward, et al.. (2013). Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. Clinical Cancer Research. 19(6). 1534–1546.
14.
Mark, Tomer M., et al.. (2013). Management of Double-Refractory Multiple Myeloma. Current Hematologic Malignancy Reports. 8(4). 253–260.
15.
Gergis, Usama, Gail J. Roboz, Tsiporah B. Shore, et al.. (2013). A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia. Biology of Blood and Marrow Transplantation. 19(7). 1040–1045.
16.
Dimopoulos, Meletios Α., Evangelos Terpos, Hartmut Goldschmidt, et al.. (2012). Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. Cancer Treatment Reviews. 38(8). 1012–1019.
17.
Mark, Tomer M., David Jayabalan, Morton Coleman, et al.. (2008). Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. British Journal of Haematology. 143(5). 654–660.
18.
Mark, Tomer M., Jessica Stern, Jessica Furst, et al.. (2008). Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma. Biology of Blood and Marrow Transplantation. 14(7). 795–798.
19.
Niesvizky, Rubén, Tara Naib, Paul J. Christos, et al.. (2007). Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy. British Journal of Haematology. 138(5). 640–643.
20.
Niesvizky, Rubén, Déborah Martı́nez-Baños, Jessica Jalbrzikowski, et al.. (2007). Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia & lymphoma. 48(12). 2330–2337.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Cristina Gasparetto Breakdown of academic impact, for papers by Christoph Heuck Breakdown of academic impact, for papers by Nikoletta Lendvai Breakdown of academic impact, for papers by P. Joy Ho Breakdown of academic impact, for papers by Yvonne A. Efebera Breakdown of academic impact, for papers by Douglas Joshua Breakdown of academic impact, for papers by Hugh D Carr-Smith Breakdown of academic impact, for papers by Masao Mizuki Breakdown of academic impact, for papers by Steven Arkin Breakdown of academic impact, for papers by Christopher S. Hourigan